Thromgen, Inc.

Ann Arbor, MI 48107

SBIR Award Summary

Total Number of Awards 11
Total Value of Awards $2.29MM
First Award Date 04/01/96
Most Recent Award Date 06/01/06

Key Personnel

Last Name Name Awards Contact
Hasan Ahmed A.K. Hasan 7
Schmaier Alvin H Schmaier 3
Morinelli Thomas Anthony Morinelli 1

11 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-04-28
Budget: 06/01/06 - 11/30/07

DESCRIPTION (provided by applicant): The purpose of this proposal is for Thromgen, Inc. to transition its preclinical agent, Thrombostatin(tm), into human clinical trials. Thromgen, Inc. has created an agent that is a low affinity direct thrombin inhibitor and a higher affinity binder to the thrombin activation site on both human protease rec...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-04-28
Budget: 06/01/05 - 05/31/06

DESCRIPTION (provided by applicant): The purpose of this proposal is for Thromgen, Inc. to transition its preclinical agent, Thrombostatin(tm), into human clinical trials. Thromgen, Inc. has created an agent that is a low affinity direct thrombin inhibitor and a higher affinity binder to the thrombin activation site on both human protease rec...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/01 - 07/31/03

DESCRIPTION (provided by applicant): Recent evidence indicates that the ACE breakdown product of BK, Arg-Pro-Pro-Gly-Phe (RPPGF), possesses its own unique activities. RPPGF interacts with a-thrombin and protease activated receptor 1 (PAR1) to inhibit thrombin activation of platelets. RPPGF also has been shown to amel...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/01 - 03/31/04

DESCRIPTION (Applicant's Description Verbatim): The hypothesis of this proposal is that a thrombin inhibitor that selectively interferes with platelet activation will be an important therapeutic agent in the management of acute coronary syndromes. Thromgen, Inc. is developing a class of agents called thrombo...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/00 - 08/31/01

DESCRIPTION: (Adapted from the Investigator's Abstract): the purpose of this proposal is to extend the results from a phase 1 STTR and characterize the in vivo efficacy of thrombostatin, a novel peptide that inhibits gamma-thrombin from activating platelets. Thrombostatin will be tested alone and as part of combina...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/99 - 08/31/00

DESCRIPTION: (Adapted from the Investigator's Abstract): the purpose of this proposal is to extend the results from a phase 1 STTR and characterize the in vivo efficacy of thrombostatin, a novel peptide that inhibits gamma-thrombin from activating platelets. Thrombostatin will be tested alone and as part of combina...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 05/15/99 - 04/14/00

DESCRIPTION (adapted from applicant's abstract): The purpose of this proposal is to evaluate the in vivo efficacy of a new class of thrombin inhibitors, designated as thrombostatins. Thrombostatins are a group of agents that prevent a and g -thrombins from activating platelets. Thrombostatins prevent thrombin from ac...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/98 - 07/31/99

DESCRIPTION (Adapted from applicant's abstract): The purpose of this proposal is to establish the in vivo efficacy of a new class of thrombin inhibitors, thrombostatins. Thrombostatins are a group of agents that prevent alpha and gamma thrombus from activating platelets. Thrombostatins prevent ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/98 - 08/31/99

The purpose of this project is to develop a selective inhibitor of alpha- thrombin~s activation of platelets and other cells by blocking its ability to cleave the cloned thrombin receptor. This agent, which is called thrombostatin, does not interfere with alpha-thrombin~s ability to form fibrin clots. The spec...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/97 - 04/30/98

The purpose of this project is to develop a selective inhibitor of alpha- thrombin~s activation of platelets and other cells by blocking its ability to cleave the cloned thrombin receptor. This agent, which is called thrombostatin, does not interfere with alpha-thrombin~s ability to form fibrin clots. The spec...

Load More